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The netrin-like (NTR) domain is a feature of several extracel-
lular proteins, most notably the N-terminal domain of tissue
inhibitors of metalloproteinases (TIMPs), where it functions as
a strong inhibitor of matrix metalloproteinases and some other
members of themetzincin superfamily. The presence of a C-ter-
minal NTR domain in procollagen C-proteinase enhancers
(PCPEs), proteins that stimulate the activity of astacin-like
tolloid proteinases, raises the possibility that this might also
have inhibitory activity. Here we show that both long and short
forms of the PCPE-1 NTR domain, the latter beginning at the
N-terminal cysteine known tobe critical forTIMPactivity, show
no inhibition, at micromolar concentrations, of several mem-
bers of themetzincin superfamily, includingmatrixmetallopro-
teinase-2, bone morphogenetic protein-1 (a tolloid proteinase),
and different ADAMTS (a disintegrin and a metalloproteinase
with thrombospondin motifs) proteinases from the adamalysin
family. In contrast, we report that the NTR domain within
PCPE-1 leads to superstimulation of bone morphogenetic
protein-1 activity in the presence of heparin and heparan sul-
fate. These observations point to a new mechanism whereby
binding to cell surface-associated or extracellular heparin-like
sulfated glycosaminoglycans might provide a means to acceler-
ate procollagen processing in specific cellular and extracellular
microenvironments.
It is now well established that different associations of mod-
ules in multidomain proteins can provide increased diversity
and specificity of function in many areas of cell biology, includ-
ing receptor signaling, enzyme (particularly proteinase) activ-
ity, and extracellular matrix function. The NTR6 domain (1),
found solely in extracellular proteins, occurs in TIMPs (2),
agrin (3, 4), netrins (5), complement proteins C3/C4/C5 (6),
secreted frizzled-related proteins (7), growth and differentia-
tion factor binding proteins (8), ADAMTSL-5 (9), and procol-
lagen C-proteinase enhancers (PCPE-1 and -2) (10, 11).
In the TIMPs, the NTRmodule corresponds to the N-termi-
nal domain, which forms a tight 1:1 complexwith the active site
ofMMPs, thereby inhibiting their activity (12, 13).Within such
complexes, the TIMP N-terminal cysteine residue plays a key
role in expelling the catalytic water molecule bound to the zinc
atom in the MMP active site (12, 13), such that addition of an
alanine residue at the N terminus abolishes TIMP inhibition
(14). The identification of NTR domains in proteins other than
TIMPs prompted the suggestion that these proteins might also
be involved in the regulation of metalloproteinase activity (1).
In agrin (4), the NTR domain (also called NtA) also occurs at
the N terminus of the molecule, and its three-dimensional
structure (an OB-fold) is strikingly similar to that of TIMP-1
(3). In contrast, however, the first residue in agrin, just before
the TIMP-like cysteine, is an asparagine, and there have been
no reports of TIMP-like inhibitory activity of the agrin NTR
domain.
In all of the other NTR domain-containing proteins, this
domain occurs in the C-terminal region, suggesting that pro-
teolytic release of the NTR domain would be a prerequisite for
possible TIMP-like activity. One such protein is PCPE-1, an
ECM protein that is devoid of intrinsic proteolytic activity but
that stimulates the action of tolloid proteinases in a substrate-
specific manner (15, 16). PCPE-1 and PCPE-2 consist of two
CUB (module found in complement subcomponents Clr/Cls,
Uegf, and BMP-1) domains separated from a C-terminal NTR
domain by a protease-sensitive linker. Some years ago, NTR
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domain-containing fragments from PCPE-1 with apparent
TIMP-like activity were identified in the culture medium of
brain tumor cell lines (17). Unlike TIMP-2, however, which
inhibited MMP-2 cleavage of a quenched fluorescent peptide
with an IC50 value of 1.6 nM, these fragments appeared to be
rather weak MMP-2 inhibitors (IC50  500 nM) (17). Since
then, the three-dimensional structure of the PCPE-1 NTR
domain was solved (10), but no evidence of inhibitory activity
was obtained, against a range of metalloproteinases including
MMPs-1, -2, -3, and -9, and tumor necrosis factor- converting
enzyme (TACE/ADAM-17), as well as the serine proteinases
trypsin, plasmin, kallikrein, and thrombin. It should be noted,
however, that both the fragments studied byMott et al. (17) and
the constructions of Liepinsh et al. (10) included several resi-
dues N-terminal to the TIMP-like terminal cysteine, which
might be expected to interferewith inhibitory activity. Thus the
role of the NTR domain in PCPE-1 remains unclear.
Information on the roles of the NTR domains in the other
NTR domain-containing proteins is limited. There have been
no reports of proteinase inhibitory activity in theNTR domains
of netrins, complement proteins C3/C4/C5, or the growth
and differentiation factor binding proteins WFIKKN1 and
WFIKKN2. In contrast, this domain is frequently implicated in
binding to heparin or related macromolecules. TIMP-3, for
example, binds to sulfated glycosaminoglycans of the ECM (18)
or to other sulfated oligosaccharides (19), interactions that
enhance its inhibitory activity against MMP-2 (20), ADAMTS-2
(21), ADAMTS-4 (19, 22), and ADAMTS-5 (19). Similarly,
PCPE-1 binds to heparin (23) via its NTR domain, as does
netrin-1 to sulfated glycosaminoglycans of the ECM (24).
Here we show that the NTR domain of PCPE-1, in both long
and short forms, is not an inhibitor of representative members
of the metzincin superfamily, including MMPs, ADAMTSs,
and the tolloid proteinase BMP-1. On the other hand, this
domain is involved in relatively weak binding toMMP-2 and to
BMP-1. Strikingly, in the presence of both PCPE-1 and heparin
or heparan sulfate, we found that the activity of BMP-1 is fur-
ther stimulated, an effect requiring the presence of the NTR
domain, with implications for cell surface and ECM control of
procollagen processing.
EXPERIMENTAL PROCEDURES
Reagents—Unless otherwise stated, all of the reagents were
obtained from Sigma-Aldrich, including the two forms of hep-
arin (H-3149 and H-3393), both with a molecular mass of
17–19 kDa (according to the manufacturer), from porcine
intestinal mucosa. In addition, heparin and heparan sulfate
were obtained from Iduron (Manchester, UK), also from por-
cine mucosa. Acid-soluble rat tail type I collagen was from BD
Biosciences and Brij 35 (oxidant-free) from Uptima.
Recombinant Proteins—Recombinant human BMP-1, BMP-
1-FLAG, Myc-tagged mini-procollagen III, PCPE-1, PCPE-1His,
and its CUB2-NTR fragmentwere expressed in 293-EBNAcells
and purified as described (16, 25, 26). For some experiments,
recombinant PCPE-1 and the C-propeptide trimer of procolla-
gen III were produced in insect cells (baculovirus system), as
also described (23, 27). In addition to BMP-1, other recombi-
nant human proteinases were produced as follows: MMP-2 in
NSO cells (28) and ADAMTS-2, ADAMTS-4, and ADAMTS-5
in 293-EBNA cells (29–31). In all cases, the protein concentra-
tions were determined by the Bradford assay (Pierce).
Production of NTRs and NTRt—By homology with the
TIMPs, the NTR domain of human PCPE-1 begins with the
cysteine residue at position 318 in the full-length protein
(including the signal sequence; see Fig. 1) (1). To produce this
fragment (called NTRshort or NTRs), a construct coding for
the human PCPE-1 signal sequence followed immediately by
the NTR domain was produced by PCR, using the QuikChange
XL site-directed mutagenesis kit (Stratagene), followed by liga-
tion with T4 DNA ligase (rapid DNA ligation kit; Fermentas),
from a pCEP4 vector containing the full-length coding region
(plus an 8-histidine tag) (25), using the following primers: 5-
GCCCTGGGCAAAAGGCAGCAG-3 (antisense, 3 extrem-
ity of signal peptide) and 5-TGCCCAAAGCAGTGCCGC-
CGG-3 (sense, 5 extremity of NTR domain). After sequence
verification (Genome Express, Grenoble, France), HEK 293-
EBNA cells were transfected as described (16), and conditioned
mediumwas collected every 2 days for up to 3 weeks. NTRswas
then purified from the medium by nickel affinity chromatogra-
phy (nickel-nitrilotriacetic acid; Qiagen), as described (25), fol-
lowed by heparin affinity chromatography (Heparin Sepharose
6 Fast Flow; GE Healthcare). Briefly, fractions from the nickel-
nitrilotriacetic acid column were diluted 3 in 20 mM HEPES,
pH 7.4, then loaded onto the heparin column, and eluted with a
0.15 to 0.75 M NaCl gradient. Pooled fractions were then con-
centrated using Amicon Ultra centrifugal filter devices (molec-
ularmass cut-off, 10 kDa). For the preparation of the other form
of the NTR domain used in this study, called NTRtrypsin or
NTRt, containing the entire NTR domain plus part of the
CUB2-NTR linker region, full-length PCPE-1His or CUB2-
NTR was subjected to limited proteolysis with immobilized
trypsin, and the releasedNTRt was purified as described (26). It
should be noted that trypsin treatment removes the His tag at
the C terminus of both PCPE-1His and CUB2-NTR.
Circular Dichroism Spectroscopy—To evaluate the folding of
NTRs and NTRt, far UV (180–260 nm) circular dichroism
measurements were carried out using thermostatted 0.2-mm-
path length quartz cells in an Applied Photophysics Chirascan
instrument, calibrated with aqueous d-10-camphorsulfonic
acid. Proteins ( 0.4 mg/ml) were analyzed at 25 or 65 °C in 20
mM Tris-H2SO4, 150 mM NaF, pH 7.4. The spectra were mea-
sured with a wavelength increment of 0.5 nm, an integration
time of 8 s, and a bandpass of 1 nm.
Cleavage of PCPE-1 by MMP-2—To determine the MMP-2
cleavage sites in PCPE-1, recombinant MMP-2 was first auto-
activated by preincubation for 15 min at 37 °C and then incu-
bated (at a final concentration of 150 nM) for 8 h at 37 °C with
PCPE-1His (1.45 M) in 25 mM Tris-HCl, pH 7.5, 0.15 M NaCl,
5 mM CaCl2 in a final volume of 50 l. The reaction products
were separated by 12% SDS-PAGE (under reducing conditions)
and then transferred to a polyvinylidene difluoride membrane.
After Coomassie Blue detection, N-terminal sequencing was
carried out at the common sequencing center of IFR128 Bio-
sciences (Lyon, France).
Effect of PCPE-1NTR onMMPActivity—Potential inhibitory
activity of the insect cell-derived NTR fragment was assayed
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with purified MMP-1 (collagen substrate), MMP-2 (gelatin
substrate), andMMP-3 andMMP-7 (both casein substrates), as
described (32). Potential inhibition ofMMP-2 activity by NTRs
and NTRt fragments was also followed using the quenched
fluorescent substrate Mca-PLGL-Dpa-AR-NH2 (Calbiochem),
as described (33). The reactions were carried out in microtiter
plates in a total volume of 100l. Briefly,MMP-2 (final concen-
tration, 17 nM)was first activated by preincubation for 10min at
37 °C in buffer A (100 mM Tris-HCl, pH 7.5, 100 mM NaCl, 10
mM CaCl2, 0.02% octylglucoside). NTRs or NTRt was then
added to a final concentration of 1 M (as well as 0.25 mM
Pefabloc in the case of NTRt, to inhibit potential residual tryp-
sin activity), and the reactions were initiated by the addition of
substrate to a final concentration of 1.14 M. Enzyme activity
was measured, using a TECAN spectrofluorimeter, from the
increase in fluorescence over the first 5 min of the reaction.
Excitation and emission wavelengths were set at 328 and 390
nm, respectively.
The effects of NTRs and NTRt on MMP-2 cleavage of dena-
tured collagen were also tested using acid-soluble rat tail ten-
don collagen I, after denaturation for 30min at 60 °C. The reac-
tions were carried out in buffer A for 1 h at 37 °C using 0.37 M
collagen, 17 nM MMP-2, and up to 2 M NTRs or NTRt and
then analyzed by SDS-PAGE (12% acrylamide in the separating
gel) in the presence of 20 mM dithiothreitol. The gels were
stained with Coomassie Blue.
Effect of PCPE-1 NTR on BMP-1 Activity—To determine the
effects of the different forms of PCPE-1 NTR on the activity of
BMP-1, fluorescently labeled mini-procollagen III substrate
(26) (150 nM)was incubatedwith 12 nMBMP-1-FLAGand 1M
NTR (with 0.25 mM Pefabloc in the case of NTRt) in 50 mM
HEPES, pH 7.4, 0.15 M NaCl, 5 mM CaCl2, 0.02% Brij-35 for 2 h
at 37 °C (final volume, 20l). The reactionswere stopped by the
addition of 10 l of 3 Laemmli sample buffer (without brom-
phenol blue), followed by heating at 100 °C for 5 min and anal-
ysis by discontinuous SDS-PAGE (7.5% acrylamide in the sep-
arating gel). Quantitation was done on a Molecular Dynamics
Storm 860 imager using the red laser (635 nm).
Activity was also analyzed using the quenched fluorescent
substrate Mca-YVADAPK(Dnp)-OH (Bachem) in microtiter
plates at a concentration of 20 M with 0–2 MNTR (and 0.25
mM Pefabloc in the case of NTRt) in 50 mM Tris-HCl, pH 7.4,
0.15 M NaCl, 5 mM CaCl2, 0.02% octylglucoside. BMP-1-FLAG
was then added to a final concentration of 36 nM, in a total
volume of 100l, and subsequent changes in fluorescence were
monitored at 405 nm (excitation at 330 nm) in a TECAN spec-
trofluorimeter for 30 min at 37 °C.
Effects of PCPE-1NTR onADAMTS-2 Activity—ADAMTS-2
activity was assayed by release of the N-propeptides from a
14C-labeled pN-collagen I substrate, as described (34). Briefly,
substrate (240 nM) was incubated with recombinant ADAMTS-2
(2 nM) for 18 h at 26 °C in 50 mM Tris, pH 7.5, 500 mM NaCl, 2
mMCaCl2, 2.5mMN-ethylmaleimide, 0.5mMphenylmethylsul-
fonyl fluoride, 0.02% Brij 35 (final volume, 125 l) in the pres-
ence of increasing concentrations of NTR (0–2.5 M). The
amount ofN-propeptide releasedwasmeasured by scintillation
counting of the supernatant after ethanol precipitation of col-
lagen product and uncleaved substrate. Themeasured activities
were corrected for nonspecific activity by the subtracting values
for control assays carried out in the presence of 50 mM EDTA.
Effects of PCPE-1 NTR on the Activities of ADAMTS-4 and
ADAMTS-5—Activities of ADAMTS-4 (form 2, without the
spacer domain (30)) and ADAMTS-5 (form 4; without the cys-
teine-rich, spacer and second thrombospondin domains (31))
were assayed using the quenched fluorescent substrate FAM-
AELQGRPISIAK-TAMRA, as described (22). Briefly, prote-
ase (ADAMTS-4 or ADAMTS-5, 1 nM) was preincubated for
2 h at 37 °C with different concentrations of NTR fragment in
50 mM Tris-HCl, pH 7.5, 0.15 M NaCl, 10 mM CaCl2, 0.02%
NaN3, 0.05% Brij-35. Fluorescent substrate was then added to a
concentration of 0.5 M (final volume, 200 l), and activity was
measured by the increase in fluorescence at 535 nm after exci-
tation at 485 nm using a Gemini SpectraMax (Molecular
Devices) spectrofluorimeter. Peptide hydrolysis was measured
for 2 h at 37 °C.
Surface PlasmonResonance—Protein interactionswere stud-
ied by surface plasmon resonance experiments using a Biacore
T100 instrument (GE Healthcare) at the protein production
and analysis facility of IFR128 Biosciences. BMP-1 was im-
mobilized in 10 mM sodium acetate buffer, pH 4.5, on a CM5
sensor chip (series S, noncertified) using amine coupling
chemistry. The control channel was prepared with the same
activation/deactivation procedure except that the BMP-1 solu-
tion was replaced by buffer alone. Prior to injection, the ana-
lytes were dialyzed against HBS (10 mM HEPES, pH 7.4, 0.15 M
NaCl) containing 5 mM CaCl2, which was also used as running
buffer after the addition of 0.05% P-20. Sensorgrams were
recorded at 25 °C with flow rates of 30 or 50 l/min. Regener-
ation of active and control channels was performed using 50%
ethylene glycol followed by 2 MNaCl.MMP-2 was immobilized
in the same way, but the surface was regenerated using 2 M
guanidium chloride.
For the analysis of kinetic experiments, double referencing
(subtraction of the control sensorgram and then subtraction of
a sensorgram obtained with buffer alone) were used. Because it
was not possible to fit the association and dissociation curves
shown in Fig. 4A using the usual binding models, responses
during the association phase were plotted against 1/t, and a
linear fit was used to calculate steady state values at infinite time
(36). These values were then plotted against PCPE-1 concen-
trations, and the curve was fitted using the equation RUeq 
(Rmax1  [PCPE-1]/(KD1  [PCPE-1]))  (Rmax2  [PCPE-1]/
(KD2 [PCPE-1])) with Kaleidagraph software.
For experiments with heparin, streptavidin (5000–6000 RU)
was first immobilized as described (35) on both active and con-
trol channels. Biotinylated heparin was then injected on the
active channel to reach a level of immobilization of 40–50 RU,
and the surface was conditioned with two pulses of 1 M NaCl.
Protein solutions for injectionswere prepared in 10mMHEPES,
pH 7.4, 0.15 M NaCl, and 0.05% P20, which was also used as
running buffer. A flow rate of 30 l/min was used, and regen-
eration was achieved with injections of 1 or 2 M NaCl.
Co-immunoprecipitation of PCPE-1 with BMP-1—To study
the possible interaction of BMP-1 with PCPE-1, 200 nM BMP-
1-FLAG was preincubated with an equimolar quantity of
PCPE-1His in 50 mM Tris, pH 7.5, 0.15 M NaCl, 5 mM CaCl2
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(total volume, 200 l) for 1 h at 4 °C. Meanwhile 50 l of anti-
FLAG M2 affinity gel slurry (Sigma) was equilibrated in the
same reaction buffer. The protein mixture was then incubated
with the anti-FLAG-agarose for 3 h at 4 °C, rotating continu-
ously. The suspension was then loaded into 500-l spin cups
(Pierce) andwashed five times with 50l of 50mMTris, pH 7.5,
150 mM NaCl, 1% Triton X-100 by pulse centrifugation, and
then proteins were eluted with 100 mM glycine, pH 2.5. The
eluates were analyzed by 10% SDS-PAGE under nonreducing
conditions. The gels were then blotted onto polyvinylidene
difluoride membranes, and the proteins were detected using a
polyclonal rabbit PCPE-1 antibody (36) followed by an horse-
radish peroxidase-labeled anti-rabbit secondary antibody. The
blots were developed using a Chemi-Doc luminescence visual-
ization scanner (Bio-Rad).
Effect ofHeparin onStimulation ofBMP-1Activity byPCPE-1—
To investigate the effects of heparin and heparan sulfate
on BMP-1 activity in the presence and absence of PCPE-1 or
its fragments, BMP-1-FLAG (5 or 10 nM) was incubated (in
LoBind Eppendorf tubes) at 37 °C for 10–30 min (or longer
in the absence of PCPE-1) with mini-procollagen III (200
or 400 nM, added last), with or without PCPE-1His,
CUB1CUB2, NTRt, or a mixture of CUB1CUB2 and NTRt
(each added at equimolar concentrations with respect to
mini-procollagen III) and up to 800 g/ml heparin (or 200
g/ml heparan sulfate) in 50mMHEPES, pH 7.4, 0.15 MNaCl, 5
mM CaCl2, 0.02% Brij 35 (total volume, 25 or 50 l). In the case
of CUB1CUB2 or NTRt, 0.25 mM Pefabloc was also present.
The reactions were stopped on ice with the addition of 250 mM
EDTA, pH7.4, to a final concentration of 25mMand then either
processed directly for SDS-PAGE by the addition of 5 Lae-
mmli sample buffer or first trichloroacetic acid/acetone precip-
itated and pretreatedwith 8Murea for 5min at 100 °C (26) prior
to the addition of sample buffer and then heated for 3 min at
100 °C. The reaction products were then separated on Ready
Gel precast acrylamide gels (Bio-Rad; 7.5% or 4–20% acrylam-
ide in the separating gel; nonreducing conditions) followed by
staining with Coomassie Blue. Alternatively, for quantitation,
the gels were stained with SYPRO Ruby (Sigma) and then
scanned on a Molecular Dynamics STORM 860 imager (blue
laser; wavelength, 450 nm). The extent of cleavage of the mini-
procollagen III substrate was determined using ImageQuant
5.2 software and expressed as the total intensity in the
C-propeptide trimer andN-terminal fragment peaks divided by
the total intensity of substrate and products.
RESULTS
Effects of PCPE-1 NTR onMMPs—
Following the report of Mott
et al. (17) identifying NTR domain-
containing fragments of PCPE-1
as apparently weak inhibitors of
MMP-2, we first sought to explore
these observations using different
forms of NTR domain prepared
either by proteolysis or by directed
mutagenesis. Initially, using a bacu-
lovirus system for expression of
recombinant human PCPE-1 in
insect cells (23), we purified a formof theNTRdomain from the
medium that arose by spontaneous proteolysis of the full-
length protein. By N-terminal sequencing, we determined that
this form (called NTRbaculovirus or NTRb) also included the
entire linker between the CUB2 and NTR domains as well as
the six C-terminal residues from the CUB2 domain (Fig. 1).
We found no detectable inhibition by NTRb of purified
MMP-1 (collagen substrate), MMP-2 (gelatin substrate), and
MMP-3 and MMP-7 (both casein substrates) at concentra-
tions up to 5 M (data not shown).
Because the baculovirus form of PCPE-1 NTR included the
entire linker between the CUB2 and NTR domains, in contrast
to the forms identified by Mott et al. (17) where cleavage
occurred within the linker region, we also tested the effects of a
form of the PCPE-1 NTR domain (NTRt) prepared by limited
proteolysis of full-length PCPE-1 with immobilized trypsin.
N-terminal sequencing showed that NTRt consisted of three
forms starting in the CUB2-NTR linker region at Val294, Ser300,
or Thr306 (numbering for full-length PCPE-1 including the
signal peptide; Fig. 1). Furthermore, because structural stud-
ies on TIMPMMP complexes have shown the importance of
the N-terminal cysteine in the mechanism of inhibition (2,
12–14), we also produced, by targeted mutagenesis, an addi-
tional form of PCPE-1 NTR, called NTRs, starting precisely at
the first cysteine residue (Cys318; Fig. 1), as confirmed byN-ter-
minal sequencing.
By circular dichroism spectroscopy, NTRs and NTRt were
found to have similar spectra in the 180–260-nm range (Fig. 2)
and similar to that of recombinant PCPE-1 NTR previously
used for structural studies (1, 10). In addition, this domain was
found to be remarkably stable to temperature, with a CD spec-
trum that remained essentially unchanged in the temperature
range 25–65 °C (Fig. 2). We conclude that both NTRs and
NTRt were correctly folded.
We then tested the effects of NTRs and NTRt on the activity
of purified MMP-2, using a quenched fluorescent peptide
substrate. In both cases, we found less than 5% inhibition of
MMP-2 activity at a NTR concentration of 1 M (Fig. 3). We
also tested the effects of both forms ofNTRonMMP-2 cleavage
of denatured collagen I but found no evidence of inhibition at a
NTR concentration of 2 M (supplemental Fig. S1).
We conclude that the NTR domain of PCPE-1 is not an
inhibitor ofMMP-2. In agreementwith this lack of inhibition of
MMP-2, NTR binding to immobilized MMP-2 (1832 RU) was
FIGURE1.Aminoacid sequenceofhumanPCPE-1 in the regionof theCUB2-NTR linker, showing the start
positions of the NTR containing fragments previously identified by Mott et al. (17) and the N-terminal
sequence of the construct used by Liepinsh et al. (10), as well as the MMP-2 cleavage site determined
here and the start positions of the different forms of NTR used in this study.
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assayed using Biacore technology, and both forms of NTRwere
found to bind only weakly to MMP-2, with dissociation con-
stants at least 1 M (data not shown).
In addition, as previously reported (37), we found that full-
length PCPE-1 was itself a substrate for MMP-2, although
cleavage was relatively inefficient, requiring long incubations at
high enzyme concentrations. By N-terminal sequencing, we
found the cleavage site to be localized at the Pro286–Lys287 bond
in the CUB2-NTR linker region (Fig. 1), i.e. N-terminal to the
serine protease sites identified by Mott et al. (17).
Effects of PCPE-1 NTR on Other Metzincins—We also tested
the effects of NTRs and NTRt on other members of the metz-
incin superfamily, not previously assayed elsewhere (10, 17),
including BMP-1, and ADAMTS-2, -4, and -5. Using fluores-
cently labeledmini-procollagen III as a substrate for BMP-1, we
found no evidence of inhibition by either form of NTR at a
concentration of 1 M (Fig. 3). This lack of inhibitory activity
was confirmed using a quenched fluorescent peptide substrate
(supplemental Fig. S2). Using a pN-collagen substrate (i.e. pro-
collagen without the C-propeptide region), we also tested the
effect ofNTRs andNTRt onN-terminal procollagen processing
by ADAMTS-2 (Fig. 3). Again, no significant inhibition was
seen by either form of NTR up to concentrations of 2.5 M.
Similar results were obtained for ADAMTS-4 and -5, using a
quenched fluorescent peptide substrate (supplemental Fig. S2).
We conclude that the NTR domain of PCPE-1 is not an inhib-
itor of BMP-1 or ADAMTS-2, -4, or -5.
Role of NTR within PCPE-1—It has previously been reported
(38) that PCPE-1 binds to mTLL-1, which, like BMP-1, is also a
member of the tolloid family butwhich consists of an additional
EGF-CUB-CUBmotif at theC terminus. Todeterminewhether
PCPE-1 also binds to BMP-1, we studied the interaction by
surface plasmon resonance (Biacore Technology). As shown in
Fig. 4A, full-length PCPE-1 was found to bind to immobilized
BMP-1, in a concentration-dependent manner. Although a
weak signal could already be detected when a 12.5 nM solution
of PCPE-1 was injected, saturation was not reached even at 6.4
M PCPE, showing that several binding processes were occur-
ring. Because the experimental curves (fast association and dis-
sociation phases followed by slower phases) could not be fitted
FIGURE 2.Circular dichroismspectra of thePCPE-1NTRdomain. The spec-
tra for NTRs and NTRt were measured at 25 °C, and that for NTRt was also
measured at 65 °C.
FIGURE 3. Effects of NTRs and NTRt on the activities of MMP-2, BMP-1,
and ADAMTS-2. MMP-2 activity was assayed on a quenched fluorogenic
peptide (NTR concentration, 1 M), BMP-1 activity was assayed on fluores-
cently labeled mini-procollagen III (NTR concentration, 1 M), and
ADAMTS-2 activity was assayed on radioactively labeled pN-collagen I
(NTR concentration, 2.5 M). The activities are expressed relative to activ-
ity in the absence of NTR, for each enzyme/substrate combination. The
error bars show standard deviations. FIGURE 4. Binding of PCPE-1 to BMP-1 studied by surface plasmon reso-
nance (Biacore). A, concentration dependence of binding of full-length
PCPE-1 (12.5, 25, 50, 100, 200, 400, 800, 1600, 3200, and 6400 nM) to immobi-
lized BMP-1 (500 RU). Inset, fit of the response at infinite time (RU eq) as a
function of PCPE-1 concentration using the equation given under “Experi-
mental Procedures.” B, interactions of PCPE-1 fragments CUB1CUB2, NTRt,
and CUB2-NTR (all at 500 nM) with immobilized BMP-1 (1463 RU).
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with the usual binding models, we used steady state analysis
with extrapolation to infinite time to obtain responses at equi-
librium (36). As expected, better fits to the data were obtained
assuming two binding sites (2 3 RU2) than one binding site
(2  253 RU2). The calculated KD values for the two binding
sitesmodel were 129 19 nM (accounting for 16% of the signal)
and 5.2 0.5 M (accounting for 84% of the signal). This inter-
action of PCPE-1 with BMP-1 was confirmed by co-immuno-
precipitation (data not shown) using BMP-1-FLAG and PCPE-
1His at concentrations of 200 nM.
To study which domains of PCPE-1 were involved in the inter-
action with BMP-1, we measured interactions with PCPE-1 frag-
ments. As shown in Fig. 4B, binding of the CUB1CUB2 fragment
was essentially nonexistent, whereas binding of NTRt to immobi-
lized BMP-1 was clearly apparent. (Similar observations were
made by dot blot analysis, data not shown.) It should be borne in
mind that the Biacore signal is proportional to themass of analyte
bound.Therefore, because themassofNTRt (16kDa) is approx-
imately one-half that ofCUB1CUB2 (30 kDa), binding of theNTR
domain would appear greater after correcting for differences in
molecular mass. However, the signal with the CUB2-NTR frag-
ment (33 kDa) was even higher and comparable with binding of
the full-length protein. Because CUB2 itself does not appear to
bindBMP-1, fromthe lackofbindingof theCUB1CUB2fragment,
this suggests that bindingofPCPE-1 toBMP-1occurs via theNTR
domain, with a further contribution from the CUB2-NTR linker
region. Interestingly, as also suggested elsewhere (39), this linker
region is probably intrinsically disordered, as predictedby thepro-
gram RONN (40) (supplemental Fig. S3), and could therefore
become ordered on binding to BMP-1.
Heparin Superstimulation of PCPE-1—The NTR domain of
PCPE-1 is known to bind to heparin (23). In addition, heparin
has been reported to increase the inhibition ofMMP-2 (20) and
ADAMTS-2 (21) by TIMP-3. In view of these observations, we
investigated the effect of heparin on the stimulation of BMP-1
activity by PCPE-1. Strikingly, using the standard BMP-1 assay
with mini-procollagen III as substrate (16), we found that stim-
ulation of BMP-1 activity by PCPE-1was even further increased
by the presence of 50 g/ml heparin (Fig. 5). The same result
was obtained using three different types of heparin (see “Exper-
imental Procedures”) whether BMP-1, PCPE-1, and heparin
were preincubated together or not, prior to the addition of
mini-procollagen III. Also, control experiments showed that
the effect was not due to prevention by heparin of nonspecific
absorption of PCPE-1 to the walls of the reaction tube (data not
shown). In contrast, using the same molar concentration of
CUB1CUB2 fragment instead of full-length PCPE-1, BMP-1
activity was enhanced, as expected, but there was little addi-
tional effect of heparin. The same observation was obtained
using an equimolar mixture of CUB1CUB2 and NTRt. Also,
there was no stimulation by heparin of BMP-1 activity in the
absence of PCPE-1 or CUB1CUB2. We conclude that the NTR
domain contiguously linked to the rest of the PCPE-1 molecule
is required for “superstimulation” of BMP-1 activity by heparin
in the presence of PCPE-1.
To attempt to understand the mechanism of heparin stimu-
lation, we determined the concentration dependence using a
fixed amount of BMP-1 (typically 5 nM), equimolar amounts
(200 nM) of miniprocollagen III and PCPE-1 (for maximum
enhancement (23)), and increasing concentrations of heparin.
As shown in Fig. 6A, whereas PCPE-1 led to a6-fold increase
in BMP-1 activity, this was further increased by at least 2-fold in
the presence of heparin. The extent of superstimulation
increased with heparin concentration, reaching a plateau at
2.5 g/ml and remaining constant up to 800 g/ml (data
shown up to 100 g/ml). We also studied the effect of heparan
sulfate, which again gave rise to superstimulation (Fig. 6B) of
BMP-1 activity in the presence of PCPE-1.
To further investigate the mechanism of superstimulation,
we studied the binding of heparin to each of the molecules
involved: PCPE-1, mini-procollagen III, and BMP-1. By surface
plasmon resonance using biotinylated heparin stably immobi-
lized to a streptavidin surface, we observed binding of both
BMP-1 and mini-procollagen III when injected at a concentra-
tion of 50 nM (Fig. 7). This was also the case for PCPE-1, which
has previously been reported to bind to heparin, via the NTR
domain,with nanomolar affinity (23, 41). Interestingly, whereas
mini-procollagen III bound heparin in a rather stable manner
with a slow dissociation phase, BMP-1 displayed fast associa-
tion and dissociation phases and was washed off from the sur-
face very rapidly. Dissociation constants were found to be in the
range of 10–150 nM for PCPE-1 and mini-procollagen III and
0.5–2 M for BMP-1. In contrast, the C-propeptide trimer of
procollagen III did not bind at all to the immobilized heparin,
suggesting that the binding site for heparin is located in the
triple-helical or telopeptide regions of mini-procollagen III.
DISCUSSION
PCPE-1 NTR Is Not an Inhibitor of MMP-2, BMP-1, or
ADAMTS-2, -4, or -5—The identification of NTR containing
fragments of PCPE-1 that appeared to act as weak inhibitors of
MMP-2 (17), together with the observed structural similarities
with TIMPs (1, 10, 39), prompted the hunt for possible high
affinity targets of this domain. The presence in these fragments
FIGURE 5. Superstimulation of PCPE-1 enhancing activity by heparin.
Effect of heparin (50 g/ml; Sigma H-3393) on the activity of BMP-1 (10 nM) on
mini-procollagen III (mini III, 400nM) in thepresenceandabsenceofPCPE-1His, its
CUB1CUB2orNTRt fragments,oramixtureofCUB1CUB2andNTRt (all at400nM).
Incubations were carried out at 37 °C for 15 min. The migration positions of the
released C-propeptide trimer (CPIII) and the N-terminal fragment (Nter) are indi-
cated. Discontinuous SDS-PAGE (4–20% acrylamide in the separating gel) was
carriedout innonreducingconditions, followedbystainingwithCoomassieBlue.
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of residues N-terminal to the cysteine at the start of the NTR
domain, known to abrogate the inhibitory activity of TIMPs
against MMPs (14), suggested that if it is indeed a proteinase
inhibitor, then its mechanism of action must be somewhat
unusual. Using a form of PCPE-1 NTR with 12 residues N-ter-
minal to the first cysteine, Liepinsh et al. (10) were unable to
detect inhibitory activity against a range of MMPs, ADAM-17,
and also serine proteinases. ADAM-17 is of particular interest,
because it has been shown to be inhibited by TIMP-3 (42), and
in this case addition of an alanine residueN-terminal to the first
cysteine still results in inhibitory activity (43), although the
mechanism of inhibition is unclear (44). TIMP-3 is also known
to inhibit ADAMTS-2, -4, and -5 (21, 45). In addition, early
observations (46) suggested that PCPE-1 without the NTR do-
main was more active in enhancing procollagen C-terminal
processing than the full-length protein, suggesting possible
inhibition by NTR of tolloid proteinases. For these reasons, we
decided to investigate possible inhibitory activity, on a range of
metalloproteinases, of two forms of PCPE-1 NTR, one partially
overlapping the fragments identified byMott et al. (17) and the
other beginning precisely at the first cysteine.With both forms,
however, wewere unable to detect inhibitory activity (atmicro-
molar concentrations) against members of the three main fam-
ilies within the metzincin superfamily (47): the matrixins, the
astacins, and the adamalysins, namely MMP-2, BMP-1, and
ADAMTS-2, -4, and -5.
Previous studies (10, 39) on the PCPE-1 NTR domain have
revealed its structural similarities with TIMP-1 and TIMP-2
but also its differences, notably in relation to the structural core
of PCPE-1 NTR, which is more dynamically active (39). More-
over, structure-based alignment shows the disulfide bonding
pattern to be somewhat different between PCPE-1 and TIMP-2
(10). Also, residue 2 in TIMPs, normally Ser or Thr that enters
into the S1 specificity pocket in MMPs, is replaced by Pro or
Arg in PCPE-1 NTR, depending on the alignment (1, 10). With
regard to ECM binding, PCPE-1 NTR is more closely related to
the N-terminal domain of TIMP-3, both having relatively high
predicted isoelectric points (9.4 and 9.3, respectively), but the
results presented here show that this is not sufficient to inhibit
adamalysins as in the case of TIMP-3.
Superstimulation of PCPE-1 Enhancing Activity by Heparin—
Here we show for the first time that BMP-1 binds to PCPE-1.
This observation is consistentwith a previous report (38) on the
binding of PCPE-1 tomTLL-1, a longer form of tolloid protein-
ase, found by co-immunoprecipitation, and alsowith data using
BMP-1 deletion constructs (48). Here we show that PCPE-1
binding to BMP-1 is relatively weak, with micromolar affinity,
in comparisonwith the nanomolar affinity of the PCPE-1/mini-
procollagen III interaction (26). In addition, unlike the binding
tomini-procollagen III, which involves the CUB1CUB2 region,
binding of PCPE-1 to BMP-1mainly involves the NTR domain.
In viewof its relativelyweak affinity, however, it ismost unlikely
that the BMP-1/PCPE-1 interaction alone (i.e. in the absence of
additional cooperative interactions) will play a significant role
at the concentrations used in typical in vitro assays.
A further new finding presented here is the observation
that heparin (or heparan sulfate) leads to the superstimula-
tion of BMP-1 activity on mini-procollagen III in the pres-
ence of PCPE-1. In addition, we found essentially no super-
stimulation by heparin of BMP-1 activity in the presence of
the CUB1CUB2 fragment of PCPE-1 nor in the presence of
an equimolar mixture of CUB1CUB2 and NTRt. These
FIGURE 6. A, concentration dependence of the effect of heparin on PCPE-1
enhancing activity, determined by SDS-PAGE followed by SYPRO Ruby staining,
showing the percentage of conversion of themini-procollagen III substrate (200
nM) in the presence of BMP-1 alone (5 nM), BMP-1  PCPE-1His (200 nM), and
BMP-1  PCPE-1His  increasing concentrations of heparin. The incubations
were carriedout at 37 °C for 10min.B, concentrationdependenceof theeffectof
heparansulfateonPCPE-1enhancingactivity. Theexperimental conditionswere
as in A.
FIGURE 7. Interaction of PCPE-1, mini-procollagen III (miniIII), the procol-
lagen IIIC-propeptide trimer (CPIII), andBMP-1withheparin.Biotinylated
heparin was first bound to immobilized streptavidin to reach 44 RU and then
solutions containing50nMof eachproteinwere injected in10mMHEPES, 0.15
M NaCl, 0.05% P20 for 150 s at 30 l/min.
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observations point to a role for the NTR domain of PCPE-1,
when present in the intact full-length molecule, in the mech-
anism of BMP-1 superstimulation.
Previous observations (49), in the absence of PCPE-1, showed
that tolloid proteinase activity on procollagen I (450 kDa) can be
enhanced in the presence of high molecular mass (500 kDa) dex-
tran sulfate. This effect was attributed to the formation of a com-
plex between the procollagen and the highly sulfated polysaccha-
ride, probably involving several molecules of procollagen, which
couldbe isolatedby centrifugation for 5minat 15,000g, thereby
increasing the local concentration of the substrate (49). The effect
required both a high degree of sulfation (as also found in heparin)
and also a high molecular mass, because it was not observed with
500-kDa nonsulfated dextran nor with 17–19-kDa heparin. Our
results confirm the lack of effect of heparin alone onBMP-1 activ-
ity in the absence of PCPE-1.
PCPE-1 is known to bind to heparin, via its NTR domain (23,
41), with nanomolar affinity (41). Here we confirm this obser-
vation by surface plasmon resonance (Fig. 7) and show that
although binding of heparin to mini-procollagen III is also rel-
atively tight, binding of BMP-1 to heparin is much weaker. In
contrast, the isolatedC-propeptide trimer of procollagen III did
not bind to heparin, indicating that the heparin-binding site is
in the triple-helical or telopeptide region. By analogy with the
known heparin binding sequence GIKGHR found near the C
terminus of the collagen 1(I) chain triple-helical region (50),
we propose that the site of interaction of heparin with procol-
lagen III is an identical sequence at the same position (residues
1104–1109, numbered from the start of the signal sequence),
which also occurs in mini-procollagen III. In addition, PCPE-1
has previously been shown to bind to mini-procollagen III,
involving the CUB1CUB2 and C-propeptide regions, with
nanomolar affinity (26), forming a 1:1 complex (23). Finally,
here we show that PCPE-1 binds to BMP-1 mainly via its NTR
domain, with micromolar affinity. Taken together, these data
point to the possible formation of a complex involving all of the
reactants, as depicted in Fig. 8.
In this model, in the absence of heparin, PCPE-1 would bind
tightly to mini-procollagen III via its CUB1CUB2 region, thereby
facilitating cleavage by BMP-1, as described elsewhere (26, 36). In
the presence of heparin (Fig. 8), cooperative effects involving hep-
arin binding to PCPE-1 NTR andmini-procollagen III (also weak
binding toBMP-1), aswell as interactionsofBMP-1withNTRand
the CUB2-NTR linker, would increase the local concentration of
the reactants and/or change the way in which the enzyme is pre-
sented to the substrate, resulting in superstimulation. In contrast,
in the absence of the NTR domain (and the CUB2-NTR linker),
interaction of the CUB1CUB2mini-procollagen III complex with
heparinwould not be sufficient to lead to the above effects. Even if
theNTRwerepresentbutno longer covalently attached to the rest
of the PCPE-1molecule, therewould be no reason for it to bind to
the same heparin molecule as the CUB1CUB2mini-procollagen
III complex. The model is therefore consistent with the results
shown in Fig. 5.
In favor of such a model, we note that superstimulation
reached a plateau at a heparin concentration of 2.5 g/ml,
equivalent to140 nM, which is comparable with the concen-
trations of mini-procollagen III and PCPE-1 used in the assays
(200 nM) and therefore suggestive of a 1:1:1 heparinPCPE-
1mini-procollagen III complex. In this regard, it is of inter-
est to note that there was little indication of reduced super-
stimulation at high heparin concentrations (Fig. 6A), in
contrast to the bell shaped curves seen by Butler et al. (20) and
Wang et al. (21) in studying heparin potentiation of the inter-
action of TIMP-3 with MMP-2 or ADAMTS-2, respectively.
These data on TIMP-3 were interpreted in terms of an opti-
mum heparin concentration that allows simultaneous binding
of different reactants to the same heparin molecule, unlike the
binding to separate heparinmolecules that would occur at high
heparin concentrations. The fact that a bell-shaped curve was
not observed in the experiments reported here is consistent
with the idea that a single heparin molecule binds to a pre-
existingmini-procollagen IIIPCPE-1 complex. Such a complex
would be relatively small (200 kDa), compared with the large
dextran sulfateprocollagen I complex (1000 kDa) studied by
Hojima et al. (49), which would explain our inability to pellet
the complex by centrifugation (data not shown) in the condi-
tions used by Hojima et al. (49).
These observations point to a possible role for the NTR
domain in localizing the site of procollagen processing to
specific extracellular matrix or cell surface microenviron-
ments rich in heparin-like glycosaminoglycans, as previously
suggested by Kessler and co-workers (41, 51). Sulfated gly-
cosaminoglycans have been shown in many cases to influ-
ence proteinase activity, often in close proximity to the cell
surface. The most well documented examples are heparin
stimulation of the inhibition of thrombin by antithrombin
(52, 53) or by protein C inhibitor (54). Stimulation of activity
has also been observed, as in the case of plasmin activation by
plasminogen activators (55–57). Here we report the super-
stimulation of a proteinase enhancer by heparin (and hepa-
ran sulfate). This further adds to the rich arsenal of macro-
molecules known to affect the activities of tolloid proteinases,
including PCPEs, twisted gastrulation (58), secreted frizzled
related proteins (59–61), olfactomedin (62), and, most re-
cently, fibronectin (63).
FIGURE 8. Possible mechanism by which heparin-like glycosaminogly-
cans might superstimulate the enhancing activity of PCPE-1 in the
C-terminal processing of procollagen III. PCPE-1 binds to procollagen III
in the region of the C-propeptides with nanomolar affinity. This complex
then binds to cell surface or extracellular matrix associated heparin-like
glycosaminoglycans via interactions with PCPE-1 NTR and with procolla-
gen III. In addition, BMP-1 interacts with PCPE-1 NTR, the CUB2-NTR linker,
and heparin. These interactionsmight increase the local concentrations of
the reactants and/or create a new recognition site that further facilitates
the action of BMP-1, resulting in superstimulation. Approximate molecu-
lar dimensions are based on known low resolution structures (27, 64, 65).
C1C2, CUB1CUB2.
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